Trained Neuroscientist Brings Vast Experience in Business Development and Preclinical Research to Accelerate Company Efforts in Developing Next-Generation Psychedelic Medicines
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has appointed Fiona Randall, B.Sc., Ph.D., a trained neuroscientist with worldwide research and management experience, as Senior Vice President of External Alliances and Scientific Strategy.
“We have a tremendous opportunity to accelerate Mindset’s growth through strategic partnerships. With Dr. Randall’s extensive experience in both neurological research and alliance management and execution, we’re excited to have her join our team,” said James Lanthier, CEO of Mindset. “Dr. Randall’s industry network and history of successfully managing complex and diverse alliances will play a crucial role in the development of future collaborations for our novel families of next-generations psychedelic compounds.”
Most recently, Dr. Randall founded FireWire Consulting LLC which provides preclinical research and business development services to biopharmaceutical companies. She also served as Senior Director and Interim Head of Alliance Management at Vertex Pharmaceuticals Inc. and Head of External Innovation at Eisai Inc. focusing on how partnering organizations combine strengths to develop innovative therapeutics for patients across a range of diseases. Dr. Randall is a renowned scientist with industry research experience with Eisai, GSK and Merck and has worked in the USA, UK, China and Japan.
“I am very excited to join Mindset at this crucial stage of the company’s remarkable growth journey. Mindset’s approach to drug development is rooted in scientific rigor and its platform of optimized psychedelic compounds broadens the opportunity of delivering mental health solutions both in the clinic and at home. Patients are at the heart of my scientific interests, and I am delighted to be back working in neurology to make medicines for people living with debilitating mental health issues. I look forward to collaborating with the company’s talented team and our strategic partner organizations to accelerate the development of Mindset’s robust portfolio of next-generation psychedelic compounds,” said Dr. Randall.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
